Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Ordinary Shares, nominal value 0.05 GBP per share
-
Shares outstanding
-
84,213,667
-
Total 13F shares
-
7,368,227
-
Share change
-
-12,722
-
Total reported value
-
$37,584,000
-
Price per share
-
$5.10
-
Number of holders
-
16
-
Value change
-
-$77,763
-
Number of buys
-
1
-
Number of sells
-
4
Institutional Holders of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) as of Q2 2019
As of 30 Jun 2019,
Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,368,227 shares.
The largest 10 holders included
Vivo Capital, LLC, ORBIMED ADVISORS LLC, NEA Management Company, LLC, Abingworth LLP, venBio Partners LLC, Novo Holdings A/S, Aisling Capital Management LP, Tekla Capital Management LLC, Polar Capital LLP, and WEDBUSH SECURITIES INC.
This page lists
16
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.